RestoredCDC.org Comparison

    Original site: www.cdc.gov/rubella/hcp/clinical-overview/index.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.
    [More]
    About Us Report Bug Compare Content
  Skip directly to site content Skip directly to search Skip directly to On This Page
          An official website of the United States government
        Here's how you know
              Official websites use .gov
              A .gov website belongs to an official government organization in the United States.
              Secure .gov websites use HTTPS
              A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
        Rubella (German Measles, Three-Day Measles)
          Explore Topics
        Search
          Search
          Clear Input
        For Everyone
          * About
          * Symptoms and Complications
          * Vaccination
          * Rubella Resources
          * Pregnancy and Rubella
          * U.S. MMR Vaccination Program
          * View all
        Health Care Providers
          * Clinical Overview
          * Vaccine Recommendations
          * View all
        Public Health
          * Lab Testing
          * View all
          Related Topics:
            Measles (Rubeola)
        View All
      search close search
          search
    Rubella Menu Close
    Rubella Menu
          search
              For Everyone
                  * About
                  * Symptoms and Complications
                  * Vaccination
                  * Rubella Resources
                  * Pregnancy and Rubella
                  * U.S. MMR Vaccination Program
                  * View All Home
              Health Care Providers
                  * Clinical Overview
                  * Vaccine Recommendations
                  * View All
              Public Health
                  * Lab Testing
                  * View All
              Related Topics
                  * Measles (Rubeola)
        View All Rubella
    Clinical Overview Vaccine Recommendations View All
July 15, 2024
  Clinical Overview of Rubella
          Key points
            * Rubella can lead to complications and death and can be prevented by vaccination.
            * Many rubella infections aren't recognized; the rash resembles many other rash illnesses.
            * Clinical diagnosis of rubella virus is unreliable. Up to half of infections may be subclinical.
            * Isolate people suspected to have rubella and report them to the local health department.
        Introduction
        Rubella virus is an enveloped, positive-stranded RNA virus classified as a Rubivirus in the Matonaviridae family.
        Incubation period
        The average incubation period of rubella virus is 17 days, with a range of 12 to 23 days. People infected with rubella are most contagious when the rash is erupting. But they can be contagious from 7 days before to 7 days after the rash appears.
        How it spreads
        Rubella is transmitted primarily through direct or droplet contact from nasopharyngeal secretions. Humans are the only natural hosts. In temperate climates, infections usually occur during late winter and early spring.
        Disease rates
        Prior to vaccine introduction:
        Before the rubella vaccine was licensed in the United States in 1969, rubella was a common disease that occurred primarily among young children. Epidemics occurred every 6 to 9 years, with the highest number of cases during the spring.
        Post-vaccine era:
        Rubella was declared eliminated (the absence of endemic transmission for 12 months or more) from the United States in 2004. However, it is still commonly transmitted in many parts of the world. As a result, less than 10 cases (primarily import-related) have been reported annually in the United States since elimination was declared. Rubella incidence in the United States has decreased by more than 99% from the pre-vaccine era.
        Because rubella continues to circulate in other parts of the world, an estimated 100,000 infants are born with congenital rubella syndrome (CRS) annually worldwide.
          Keep Reading: Global Measles and Rubella
        Clinical features
        Rubella is characterized by a mild, maculopapular rash along with lymphadenopathy, and a slight fever. About 25% to 50% of infections are asymptomatic.
        Characteristics of maculopapular rash:
          * Usually starts on the face
          * Becomes generalized within 24 hours
          * Lasts a median of 3 days
          * Occurs in 50% to 80% of people infected with rubella
        Characteristics of lymphadenopathy:
          * May precede rash
          * Often involves posterior auricular or suboccipital lymph nodes
          * Can be generalized
          * Lasts between 5 and 8 days
        Prevention
        Rubella vaccination:
        Rubella can be prevented with rubella-containing vaccine. Rubella vaccine is usually administered as the combination measles, mumps, and rubella (MMR) vaccine. The combination measles, mumps, rubella, and varicella (MMRV) vaccine can be used for children aged 12 months through 12 years.
        CDC recommends children get 2 doses of MMR vaccine. Adults born during or after 1957 should receive at least one dose of rubella-containing vaccine. Pregnant people who do not have evidence of immunity should be vaccinated immediately after giving birth.
        CDC recommends children get 2 doses of MMR vaccine. Adults born during or after 1957 should receive at least one dose of rubella-containing vaccine. Pregnant women who do not have evidence of immunity should be vaccinated immediately after giving birth.
          Keep Reading: Rubella Vaccine Recommendations
        Testing and diagnosis
          Testing recommendations for rubella‎
          Testing recommendations
              A visual tool that summarizes what test types are typically available and when to collect specimens for testing measles, mumps, rubella, and varicella.
              A visual tool summarizing available test types and when to collect specimens for testing measles, mumps, rubella, and varicella.
            See the tool
                See tool
        Clinical diagnosis of rubella virus is unreliable and should not be considered in assessing immune status. Up to half of all infections may be subclinical or inapparent. Many rubella infections are not recognized because the rash resembles many other rash illnesses.
        Healthcare providers should:
          * Consider rubella in unvaccinated patients with febrile rash illness and other rubella symptoms, especially if the person recently traveled internationally or was exposed to a person with a confirmed rubella case.
          * Promptly isolate people suspected to have rubella and report them to the local health department.
          * Collect nasopharyngeal swabs, throat swabs, or urine specimens for viral detection by polymerase chain reaction (PCR) testing and molecular typing, and blood for serology testing.
          Keep Reading: Laboratory Testing for Rubella
        Patient management
        There is no specific antiviral therapy for rubella infection.
        Isolation
        Patients with rubella should be isolated for 7 days after they develop rash.
        In settings where pregnant people may be exposed, outbreak control measures should begin as soon as rubella is suspected and should not be postponed until laboratory confirmation of cases.
        In settings where pregnant women may be exposed, outbreak control measures should begin as soon as rubella is suspected and should not be postponed until laboratory confirmation of cases.
        People at risk who cannot readily provide acceptable evidence of rubella immunity should be considered susceptible and should be vaccinated.
        People without evidence of immunity who are exempt from rubella vaccination for medical, religious, or other reasons should be excluded from affected institutions in the outbreak area until 23 days after the onset of rash in the last case of rubella.
        Unvaccinated people who receive MMR vaccine as part of rubella outbreak control may immediately return to school provided all people without documentation of rubella immunity have been excluded.
        Complications
        Rubella can lead to complications and death.
        Arthralgia or arthritis may occur in up to 70% of adult women with rubella. Rare complications include thrombocytopenic purpura and encephalitis.
        Rubella infection during pregnancy
        When rubella infection occurs during pregnancy, especially during the first trimester, serious consequences can result. These include:
          * Miscarriages
          * Fetal deaths/stillbirths
          * Severe birth defects known as CRS
          Keep Reading: About Congenital Rubella Syndrome (CRS)
        Case definitions
                Classifying Rubella Cases Flowchart
                See how to classify confirmed and probable rubella cases during investigations
              Jan. 6, 2025
                  Download
                Download
        Resources
          * Rubella | Surveillance of Vaccine-Preventable Diseases Manual
          * Red Book 2015: Rubella
          * Rubella | CDC Yellow Book 2024
          * Talking with Parents about Vaccines
        On This Page
            * Introduction
            * Incubation period
            * How it spreads
            * Disease rates
            * Clinical features
            * Prevention
            * Testing and diagnosis
            * Patient management
            * Complications
            * Case definitions
            * Resources
          Show More
          Related PagesVaccine Recommendations
          Related Pages
        * 
        Back to Top
            * Vaccine Recommendations
          View All Rubella
    Vaccine Recommendations
  July 15, 2024
      Sources Print Share
        Facebook LinkedIn Twitter Syndicate
          Content Source:
        National Center for Immunization and Respiratory Diseases; Division of Viral Diseases
      Related PagesVaccine Recommendations
      Related Pages
    * 
 
        * Vaccine Recommendations
      View All Rubella
  Back to Top
    Rubella
    Rubella is contagious. Most children and adults usually have mild illness with a rash starting on the face. Protect yourself with the MMR vaccine.
    View All
        For Everyone
          * About
          * Symptoms and Complications
          * Vaccination
          * Rubella Resources
          * Pregnancy and Rubella
          * U.S. MMR Vaccination Program
          Health Care Providers
            * Clinical Overview
            * Vaccine Recommendations
          Public Health
            * Lab Testing
        Sign up for Email Updates
    Contact Us
        Contact Us
          * Call 800-232-4636
          * Contact CDC
    About CDC
        About CDC
          * Pressroom
          * Organization
          * Budget & Funding
          * Careers & Jobs
    Policies
              * Accessibility
              * External Links
              * Privacy
              * Web Policies
              * FOIA
              * OIG
              * No Fear Act
              * Nondiscrimination
              * Vulnerability Disclosure Policy
    Languages
            Languages
              * Español
            Language Assistance
                  * Español
                  * 繁體中文
                  * Tiếng Việt
                  * 한국어
                  * Tagalog
                  * Русский
                  * العربية
                  * Kreyòl Ayisyen
                  * Français
                  * Polski
                  * Português
                  * Italiano
                  * Deutsch
                  * 日本語
                  * فارسی
                  * English
    Archive
          * CDC Archive
          * Public Health Publications
    Contact Us
      Contact Us
        * Call 800-232-4636
        * Contact CDC
    About CDC
        * Pressroom
        * Organization
        * Budget & Funding
        * Careers & Jobs
        * About CDC
    Policies
        * Accessibility
        * External Links
        * Privacy
        * Web Policies
        * FOIA
        * OIG
        * No Fear Act
        * Nondiscrimination
        * Vulnerability Disclosure Policy
    Languages
      Languages
        * Español
      Language Assistance
        * Español
        * 繁體中文
        * Tiếng Việt
        * 한국어
        * Tagalog
        * Русский
        * العربية
        * Kreyòl Ayisyen
        * Français
        * Polski
        * Português
        * Italiano
        * Deutsch
        * 日本語
        * فارسی
        * English
    Archive
        * CDC Archive
        * Public Health Publications
    HHS.gov USA.gov